Previous 10 | Next 10 |
2023-10-12 08:22:14 ET More on Beyond Meat, SELLAS Life Sciences, etc. Beyond Meat Continues To Look Potentially Beyond Repair Beyond Meat: The Core Question Here Is Liquidity Beyond Meat: Pain Is Far From Over SELLAS gains on FDA orphan drug status for its S...
2023-10-11 09:05:14 ET More on SELLAS Life Sciences SELLAS Phase 3 study for AML drug to continue without modifications Seeking Alpha’s Quant Rating on SELLAS Life Sciences For further details see: SELLAS gains on FDA orphan drug status for its SLS009
NEW YORK, Oct. 11, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today ...
NEW YORK, Oct. 10, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today ...
VANCOUVER, British Columbia, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Solaris Resources Inc . (TSX: SLS; OTCQB: SLSSF) (“Solaris” or the “Company”) announces the appointment of China International Capital Corporation Limited (“CICC”) as the Company’s ...
- 52 Relapsed and Refractory Lymphoma Patients Enrolled: 96% Alive at Last Assessment Indicating Favorable Survival Benefit - - Responses Observed Across Dose Levels with a 14.7% Clinical Response Rate Overall, 35.3% Overall Disease Control Rate, and 36.4% Clinical Response Rate in PT...
NEW YORK, Sept. 18, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) ("SELLAS" or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that Angelo...
VANCOUVER, British Columbia, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Solaris Resources Inc . (TSX: SLS; OTCQB: SLSSF) (“Solaris” or the “Company”) is pleased to announce assay results from the first two reconnaissance drill holes at the Patrimonio target confirming a si...
2023-08-22 10:24:41 ET More on SELLAS Life Sciences SELLAS falls 39% after delaying key milestone for cancer drug Sellas rises as GPS/Keytruda combo shows survival, disease control benefit in ovarian cancer trial SELLAS Life Sciences rises 9% after cancer drug shows ...
REGAL Interim Analysis Expected by Late 2023/Early 2024 Enrollment Expected to be Completed in Q4 2023 NEW YORK, Aug. 22, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical bi...
News, Short Squeeze, Breakout and More Instantly...
SELLAS Life Sciences Group Inc. Company Name:
SLS Stock Symbol:
NASDAQ Market:
SELLAS Life Sciences Group Inc. Website:
2024-07-19 10:10:00 ET July 19, 2024 (Investorideas.com Newswire) Investorideas.com , a global news source and expert investing resource, announces today's roundup of stocks to watch in the Biotech, Cleantech Sectors. The newest biotech companies are involved in blood disorder treat...
- Acute Myeloid Leukemia (AML) is the Second Most Common Hematological Malignancy in Children Often Associated with Poorer Prognosis Compared to Other Pediatric Cancers – - This Recognition Marks SELLAS’ Second RPDD Following the Designation for ALL Received Last Month - -...
NEW YORK, July 08, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today ...